IQ EQ FUND MANAGEMENT IRELAND Ltd Purchases 22,647 Shares of CRISPR Therapeutics AG (NASDAQ:CRSP)

IQ EQ FUND MANAGEMENT IRELAND Ltd lifted its position in CRISPR Therapeutics AG (NASDAQ:CRSP - Free Report) by 166.3% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 36,264 shares of the company's stock after buying an additional 22,647 shares during the period. IQ EQ FUND MANAGEMENT IRELAND Ltd's holdings in CRISPR Therapeutics were worth $1,427,000 as of its most recent SEC filing.

Several other hedge funds have also recently made changes to their positions in CRSP. The Manufacturers Life Insurance Company increased its holdings in shares of CRISPR Therapeutics by 1.9% in the third quarter. The Manufacturers Life Insurance Company now owns 12,477 shares of the company's stock valued at $586,000 after purchasing an additional 231 shares during the last quarter. Intellectus Partners LLC raised its stake in CRISPR Therapeutics by 3.6% in the fourth quarter. Intellectus Partners LLC now owns 7,131 shares of the company's stock valued at $281,000 after buying an additional 250 shares in the last quarter. Farrow Financial Inc. grew its position in shares of CRISPR Therapeutics by 1.4% in the 4th quarter. Farrow Financial Inc. now owns 20,097 shares of the company's stock valued at $777,000 after buying an additional 270 shares during the last quarter. Sunbelt Securities Inc. lifted its stake in CRISPR Therapeutics by 11.3% in the third quarter. Sunbelt Securities Inc. now owns 2,955 shares of the company's stock valued at $139,000 after buying an additional 300 shares during the last quarter. Finally, Kestra Private Wealth Services LLC lifted its position in CRISPR Therapeutics by 1.5% during the 4th quarter. Kestra Private Wealth Services LLC now owns 20,636 shares of the company's stock worth $812,000 after acquiring an additional 310 shares during the period. 69.20% of the stock is owned by institutional investors and hedge funds.

Remove Ads

CRISPR Therapeutics Price Performance

CRSP stock traded up $0.76 during trading on Tuesday, hitting $34.79. 668,767 shares of the company traded hands, compared to its average volume of 1,558,009. The stock's 50-day simple moving average is $42.97 and its 200 day simple moving average is $45.09. The company has a market cap of $2.98 billion, a PE ratio of -7.93 and a beta of 1.77. CRISPR Therapeutics AG has a 1 year low of $32.96 and a 1 year high of $68.39.

CRISPR Therapeutics (NASDAQ:CRSP - Get Free Report) last issued its earnings results on Tuesday, February 11th. The company reported ($0.44) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($1.15) by $0.71. CRISPR Therapeutics had a negative return on equity of 18.46% and a negative net margin of 981.54%. Research analysts expect that CRISPR Therapeutics AG will post -5.16 earnings per share for the current year.

Insider Transactions at CRISPR Therapeutics

In related news, CEO Samarth Kulkarni sold 9,973 shares of the business's stock in a transaction that occurred on Tuesday, March 11th. The shares were sold at an average price of $42.42, for a total value of $423,054.66. Following the completion of the sale, the chief executive officer now directly owns 180,890 shares in the company, valued at approximately $7,673,353.80. The trade was a 5.23 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, COO Julianne Bruno sold 1,198 shares of the business's stock in a transaction on Tuesday, March 11th. The stock was sold at an average price of $42.42, for a total transaction of $50,819.16. Following the transaction, the chief operating officer now directly owns 8,263 shares in the company, valued at approximately $350,516.46. The trade was a 12.66 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 32,381 shares of company stock worth $1,608,243. Insiders own 4.10% of the company's stock.

Analyst Upgrades and Downgrades

A number of research analysts have recently weighed in on CRSP shares. JMP Securities restated a "market outperform" rating and issued a $86.00 price target on shares of CRISPR Therapeutics in a research report on Thursday, February 13th. The Goldman Sachs Group reduced their price target on shares of CRISPR Therapeutics from $66.00 to $57.00 and set a "neutral" rating on the stock in a research report on Thursday, February 13th. Truist Financial upped their price objective on CRISPR Therapeutics from $100.00 to $120.00 and gave the stock a "buy" rating in a research note on Wednesday, February 12th. StockNews.com raised shares of CRISPR Therapeutics to a "sell" rating in a research note on Friday, March 21st. Finally, HC Wainwright reaffirmed a "buy" rating and set a $65.00 target price on shares of CRISPR Therapeutics in a research report on Thursday, February 13th. Two investment analysts have rated the stock with a sell rating, nine have assigned a hold rating and eleven have assigned a buy rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of "Hold" and an average target price of $73.11.

CRISPR Therapeutics Profile

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.